A research study titled, “Metabolomics Market by Technique and Application - Global Industry Analysis and Forecast to 2025” published by Crystal Market Research, states that the metabolomics market is projected to be around $2.5 billion by 2025.
Metabolomics is identification and quantification of the complete set of metabolites in a biological system.Metabolomics are used in wide range of applications such as drug testing, toxicological studies, and detection of diseases such as Alzheimer’s and necrosis by using biomarkers. Biomarkers are traceable substances that are inserted into an organism either for disease diagnostic or to examine health parameters. Metabolomics can also help in diagnosis of different subtypes of Alzheimer’s disease for permitting morecontrolled therapies.The biomarkers can be used for diagnosis and prognosis of malignant tumors. Metabolomics isalso used to improve the detection of various cancers such as kidney, prostate, liver, and pancreas.
High performance liquid chromatography (HPLC) segment occupied the largest share of metabolomics market in 2016 and is expected to maintain its dominance during forecast period.This can be attributed to number of factors such as high speed and accuracy of technique.Biomarker discovery segment occupied the largest share of the overall market in 2016, due to factors such as enhancement in effectiveness and reliability of metabolic profiling of biomarkers for drug discovery and diagnosing malfunction metabolites.
U.S. accounted for the major share of the North American metabolomics market in 2016, owing to factors such as easy availability of technologically advanced products, rise in adoption rate of personalized medicines, and highly developed healthcare infrastructure. Emerging markets such as China and India will exhibit favorable growth during the forecast period with rising emphasis on biopharmaceutical research and development activities in these countries.
Key players in the global metabolomics market include LECO Corporation,Agilent Technologies, Inc., Waters Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Shimadzu Corporation, Human Metabolome Technologies, Inc., Metabolon, Inc. and Bruker Corporation.Product development is the key strategy adopted by the major players operating in the global market to expand and strengthen their product portfolio and increase their market share. For instance, in May 2016,Agilent Technologies Inc. introduced The Agilent 5110 ICP-OES to its lineup of inductively coupled plasma-optical emission spectrometers. This new system will facilitate more accurate ICP-OES analysis.Likewise, in November 2016, Metabolon, Inc. launched the Meta IMD test that speeds up the diagnosis of inherent metabolic disorders.
To request a sample copy or view summary of this report, click the link below:
http://www.crystalmarketresearch.com/report/metabolomics-market
Key Findings of the Research Study:
About Crystal Market Research
Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.
Contact:
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Email: sales@crystalmarketresearch.com
Website: http://www.crystalmarketresearch.com
The global metabolomics market is expected to be around $2.5 billion by 2027. Increase in demand for personalized medicines, rapid development in pharmaceutical and biotech sectors, increase in prevalence of target diseases, and rising demand for toxicology technologies are major factors contributing to the market growth.